Loading…
Oruka Therapeutics, Inc. is projected to rise to $109.07 by 2027, a +26% move from its current price of $86.79. ORKA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $83.47 | $86.77 | $90.19 | -0.02% |
| Jul 15 | $82.12 | $86.75 | $91.63 | -0.05% |
| Jul 16 | $81.10 | $86.73 | $92.74 | -0.07% |
| Jul 17 | $80.24 | $86.71 | $93.69 | -0.10% |
| Jul 18 | $79.49 | $86.68 | $94.52 | -0.12% |
| Jul 19 | $78.82 | $86.66 | $95.29 | -0.15% |
| Jul 20 | $78.20 | $86.64 | $95.99 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $78.20 | $86.64 | $95.99 | -0.17% |
| Week 2 | $74.83 | $86.49 | $99.98 | -0.34% |
| Week 3 | $72.30 | $86.34 | $103.11 | -0.51% |
| Week 4 | $70.23 | $86.20 | $105.80 | -0.68% |
| Week 5 | $68.43 | $86.05 | $108.20 | -0.85% |
| Week 6 | $66.84 | $85.90 | $110.41 | -1.02% |
| Week 7 | $65.39 | $85.75 | $112.46 | -1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology indications. It is headquartered in Menlo Park, California.
Oruka’s lead products include ORKA-001, which targets the p19 subunit of interleukin-23 and is in phase 2a trials for PsO, and ORKA-002, which targets interleukin-17A and interleukin-17F and is in phase 2 trials for PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for a target pathway not disclosed, and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka is categorized in the Healthcare sector and focuses on developing therapies for inflammatory and immunology indications.
Oruka Therapeutics, Inc. has a current price of $85.21 and a market capitalization of $5.14B, with a market rank of 1315.
The stock’s near-term technical backdrop is described as bullish, supported by RSI14 at 60 and moving averages of $68.72 for the SMA50 and $41.96 for the SMA200. The 30-day price range runs from $64.00 to $113.45, with a support level at $55.01 and a resistance at $95.17.
The long-run price outlook is embedded in the year-by-year forecast, starting with a 2026 average around $85.21 and projecting upward through 2030 to $167.68, then to higher levels by 2040 ($432.71) and 2050 ($1,152.89) with corresponding max values reaching into the hundreds or thousands of dollars respectively.
A major floor 63.1% below — a decisive break under it would weaken the trend.
The nearest floor, 36.6% below — buyers have tended to step in here.
The nearest ceiling, 9.7% above — a clean break opens room to run.
A major ceiling 37.3% above — clearing it would confirm fresh momentum.
Key ORKA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORKA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $85.42 | Buy | $86.60 | Buy |
| MA 10 | $88.38 | Sell | $85.81 | Buy |
| MA 20 | $81.97 | Buy | $81.76 | Buy |
| MA 50 | $70.12 | Buy | $72.32 | Buy |
| MA 100 | $58.92 | Buy | $61.82 | Buy |
| MA 200 | $43.70 | Buy | $48.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.70 | Neutral |
| Stoch RSI (14) | 13.76 | Buy |
| CCI (20) | 43.55 | Neutral |
| Williams %R (14) | -64.07 | Info |
| MACD (12,26,9) | -0.49 | Sell |
| ROC (12) | 4.06 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 35.93 | Neutral |
| TRIX (15) | 1.30 | Buy |
| Awesome (5,34) | 12.56 | Buy |
| Ultimate (7,14,28) | 44.00 | Neutral |
| Momentum (10) | 0.16 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 84.90 | Buy |
| ADX (14) | 27.67 | Buy |
| ATR (14) | 2.77 | Info |
The near-term technical picture is bullish, with RSI14 at 60 and a positive tilt in momentum.
The SMA50 sits at $68.72 and the SMA200 at $41.96, indicating a constructive longer-term trend while the shorter-term price action remains above key moving averages.
The stock trades within a 30-day range of $64.00 to $113.45, with a support level at $55.01 and resistance at $95.17. These levels provide context for the potential upside and downside in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.40 | $86.79 | $113.86 | 0% | Neutral | |
| $83.48 | $109.07 | $152.62 | +26% | Bullish | |
| $83.74 | $114.04 | $167.67 | +31% | Bullish | |
| $83.85 | $118.24 | $180.64 | +36% | Bullish | |
| $119.30 | $173.54 | $273.71 | +100% | Bullish | |
| $143.49 | $214.78 | $348.28 | +147% | Bullish | |
| $152.93 | $235.16 | $390.84 | +171% | Bullish | |
| $167.47 | $264.15 | $448.91 | +204% | Bullish | |
| $157.42 | $254.43 | $441.28 | +193% | Bullish | |
| $176.77 | $292.52 | $516.97 | +237% | Bullish | |
| $255.20 | $471.24 | $900.44 | +443% | Bullish | |
| $533.41 | $1,185.37 | $2,532.26 | +12.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.40 | $86.79 | $102.12 | +0.00% |
| August 2026 | $69.04 | $82.38 | $101.56 | -5.08% |
| September 2026 | $70.42 | $84.87 | $106.28 | +3.03% |
| October 2026 | $71.16 | $86.52 | $109.76 | +1.94% |
| November 2026 | $69.55 | $85.19 | $109.26 | -1.53% |
| December 2026 | $71.27 | $87.90 | $113.86 | +3.17% |
Click any year to see its month-by-month ORKA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Oruka Therapeutics, Inc.'s 2026 outlook centres on $86.79, within a $26.40 to $113.86 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ORKA could reach as high as $152.62, with a base case around $109.07 and support toward $83.48 — roughly +26% from $86.79. Buyers look set to stay in control over this stretch.
Expect ORKA to range from $83.74 to $167.67 through 2028. The $114.04 average target implies a +31% move from current prices. That is up +5% on the projected 2027 average. Momentum favours further upside here.
The ORKA price prediction for 2029 points to an average of $118.24 (low $83.85, high $180.64) — a potential gain of +36% on today's $86.79. Buyers look set to stay in control over this stretch.
In 2030, ORKA is projected to trade between $119.30 and $273.71, averaging $173.54 — a potential gain of +100% from today's $86.79. That is up +47% on the projected 2029 average. Momentum favours further upside here.
Oruka Therapeutics, Inc.'s 2031 outlook centres on $214.78, within a $143.49 to $348.28 range. That is up +24% on the projected 2030 average. That marks a +147% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ORKA could reach as high as $390.84, with a base case around $235.16 and support toward $152.93 — roughly +171% from $86.79. Momentum favours further upside here.
Expect ORKA to range from $167.47 to $448.91 through 2033. The $264.15 average target implies a +204% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ORKA price prediction for 2034 points to an average of $254.43 (low $157.42, high $441.28) — a potential gain of +193% on today's $86.79. Momentum favours further upside here.
In 2035, ORKA is projected to trade between $176.77 and $516.97, averaging $292.52 — a potential gain of +237% from today's $86.79. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Oruka Therapeutics, Inc.'s 2040 outlook centres on $471.24, within a $255.20 to $900.44 range. That is up +61% on the projected 2035 average. That marks a +443% change versus current levels. Momentum favours further upside here.
By 2050, ORKA could reach as high as $2,532.26, with a base case around $1,185.37 and support toward $533.41 — roughly +12.7x from $86.79. Buyers look set to stay in control over this stretch.
Investing $1,000 in ORKA today (≈ 11.522065 ORKA) could be worth
$13,657.86
+$12,657.86 (+1266%) by 2050 · US Dollar
Based on the average projected ORKA price of $1,185.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORKAwould be worth at today's price.
$1,000 invested in ORKA on Jul 10, 2025 (≈ 71.073207 ORKA) would be worth
$6,168.44
+$5,168.44 (+516.8%) today · 6.17× · US Dollar
Based on a ORKA entry price of $14.07 vs. today's $86.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $85.21 | $1,018.54 | +1.9% |
| 1 month ago | $64.03 | $1,355.46 | +35.5% |
| 3 months ago | $59.58 | $1,456.7 | +45.7% |
| 6 months ago | $30.69 | $2,827.96 | +182.8% |
| 1 year ago | $14.07 | $6,168.44 | +516.8% |
| All time (5.0y) ago | $37.44 | $2,318.11 | +131.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORKA forecast.
Our base-case forecast reaches $170.00 around 2030.
Implied market cap at $170.00: $10.25B
The multi-year forecast shows a clear upside trajectory after 2026, with 2026’s average at $85.21 and 2027’s average at $105.75, while 2026’s range spans down to $26.40 and up to $115.31.
By 2030, the forecast envisions an average price of $167.68 with a min of $111.46 and a max of $273.20, delivering a projected ROI of 96.8% as bullish sentiment persists.
In 2031 the average climbs to $207.33, and by 2032 it reaches $228.38; 2033, 2034, and 2035 carry averages of $253.55, $238.82, and $279.38 respectively, with ROIs of 143.3%, 168%, 197.6%, 180.3%, and 227.9% in those years.
The forecast shows continued strength into 2040 with an average of $432.71 and a max of $866.53, representing a 407.8% ROI. By 2050 the average is $1,152.89 and the max $2,600.03, with a projected ROI of 1253%.
Overall, these estimates reflect bullish momentum across the forecast horizon, but they come with typical investment uncertainty and are not guarantees.
Tap a question to reveal the answer.
The forecast shows an average price of $167.68 in 2030, with a minimum of $111.46 and a maximum of $273.20; the implied ROI is 96.8%.
Forecasts indicate bullish sentiment from 2027 onward, with the average price rising from $105.75 in 2027 to $167.68 in 2030 and up to $1,152.89 by 2050, and ROIs climbing to 1253% by 2050. 2026 shows a neutral stance with a 0% ROI.
Yes. The 2031 forecast shows an average price of $207.33 and a max of $348.06, which exceeds $200.
The 2040 forecast lists an average price of $432.71, a minimum of $216.95, and a maximum of $866.53, with a 407.8% ROI.
The current price is $85.21 and the market cap is $5.14B.
Oruka Therapeutics, Inc. Community Discussion
0Share your Oruka Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.